Serum Institute Distances Itself From Executive s Remarks on Vaccination Drive science.thewire.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from science.thewire.in Daily Mail and Mail on Sunday newspapers.
Novavax COVID-19 Vaccine (NVX-CoV2373) Description
Novavax COVID-19 vaccine (NVX-CoV2373) (Covovax) is a prefusion protein coronavirus vaccine candidate made using Novavax’s proprietary nanoparticle technology, Matrix-M, an adjuvant to enhance immune responses and stimulate high levels of neutralizing antibodies.
Novavax Inc. s NVX-CoV2373 vaccine candidate creates an engineered baculovirus containing a gene for a modified SARS-CoV-2 spike protein. The baculovirus then infects a culture of Sf9 moth cells, which create the spike protein and display it on their cell membranes. The spike proteins are then harvested and assembled onto a synthetic lipid nanoparticle about 50 nanometers across, each displaying up to 14 spike proteins.
Malaria vaccine shows high efficacy
doi:10.1038/nindia.2021.60 Published online 28 April 2021
A malaria
vaccine, administered to African children living in a malaria-endemic region,
has proven to be up to 77 per cent effective
1.
The research,
published preprint (yet to be peer reviewed) meets the 75 per cent efficacy
goal set by the World Health Organization.
A one-year follow-up study has shown that the vaccine is well-tolerated
with mild or no adverse side effects among the children, according to an
international research team. The researchers say that it is possible to
mass-produce the vaccine at an affordable cost to better control, and
eventually eradicate, malaria.
Shares of Panacea Biotech were locked in the 10 per cent upper circuit for the second straight day, at Rs 323.70, hitting an over 12-year high on the BSE on Thursday. The stock of the biotechnology company was trading at its highest level since August 2008. It had hit a record high of Rs 487 on April 21, 2006.
Thus far in the month of April, the market price of Panacea Biotech has zoomed 83 per cent after the company and the Russian Direct Investment Fund (RDIF) agreed to produce 100 million doses of Sputnik V vaccine in India per year. In comparison, the S&P BSE Sensex has slipped 4.4 per cent so far in the current month.
Bombay HC rules in favour of Serum Institute in the trademark dispute for Covishield
SECTIONS
Share
Synopsis
A division bench of Justices Nitin Jamdar and C V Bhadang dismissed an appeal filed by pharmaceutical firm Cutis Biotech claiming trademark of the name Covishield and seeking a direction to Serum Institute of India to stop using the name for its COVID-19 vaccine.
Agencies
The court, in its order, noted that neither Cutis Biotech nor Serum Institute have a registration for the trademark Covishield .
In a major relief for Serum Institute of India (SII) Pvt Ltd, the Bombay High Court has dismissed a plea filed by Cutis Biotech that claimed to be the prior user of the trademark ‘Covishield’.